Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: To study the influence of an exponential prostate-specific antigen (PSA) decline on biochemical failure after external-beam radiotherapy (EBRT).
Methods: We analyzed 114 patients with intermediate risk prostate cancer (Gleason≤6 and PSA 10-20 or Gleason 7 and PSA <10). Patients were randomized between EBRT doses of either 70.2 Gy or 79.2 Gy (1.8 Gy per day). All patients had a follow up of at least six PSA measurements post-EBRT. Exponential decline and PSA half life were included in a Cox regression analysis for factors associated with biochemical failure.
Results: A total of 80/114 (70.2%) patterns were classified as having an exponential PSA decline. Both exponential decline (HR 0.115, 95%CI 0.03-0.44, p=0.0016) and PSA half life ratio were statistically significant predictors (HR 1.03 (95% CI 1.01-1.06)) of biochemical failure. In the model predicting for exponential decline, none of the factors were significant.
Conclusion: Patients with an exponential PSA decline show a better biochemical outcome in the long term.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canep.2011.10.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose Of Review: Prostate-specific antigen doubling time (PSADT) is a key prognostic marker in prostate cancer, especially in cases of biochemical recurrence. It guides risk stratification and therapeutic decisions, but its calculation varies significantly across institutions. This review addresses the clinical relevance of PSADT and the need for standardized methods.
View Article and Find Full Text PDFProgrammable spherical nucleic acids integrated with MOF-confined copper nanoclusters facilitate electrochemiluminescence detection of prostate-specific biomarkers.
J Mater Chem B
June 2025
Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Alpha-methylacyl-CoA racemase (AMACR) is a promising prostate cancer biomarker due to its high specificity in distinguishing prostate cancer from benign prostatic diseases. However, its low abundance in biological environments presents a significant detection challenge. To address this, we developed an innovative all-in-one s̲pherical n̲ucleic a̲cid (SNA) platform for highly sensitive and selective electrochemiluminescence (ECL) detection of AMACR.
View Article and Find Full Text PDFIn silico maturation of DNA aptamer against the prostate-specific antigen (PSA) and kinetic analysis.
Biochem Biophys Res Commun
May 2025
Department of Chemical and Materials Engineering, National Central University, Jhong-Li, 32001, Taiwan.
The detection of the prostate-specific antigen (PSA) serves as a critical marker for the diagnosis and follow-up of prostate cancer. DNA aptamers targeting PSA have been successfully screened using the systematic evolution of ligands by exponential enrichment (SELEX) technique, complemented by in silico maturation processes. In this study, we aim to optimize a truncated aptamer, denoted as TA87, through computational methods and to analyze potential aptamer candidates in the aptamer-PSA interactions.
View Article and Find Full Text PDFDevelopment of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry in Lu-PSMA-617 Radioligand Therapy.
Mol Imaging Biol
June 2025
Department of Nuclear Medicine, Clinic for Radiology and Nuclear Medicine, Goethe University Frankfurt, University Hospital Frankfurt, Theodor Stern Kai 7, D-60590, Frankfurt, Germany.
Purpose: Targeted radioligand therapy of metastatic castration-resistant prostate cancer (mCRPC) with Lu-PSMA (RLT) requires sufficient dose monitoring of the kidneys. Currently, dosimetry using SPECT/CT-imaging is the most preferred method. However, SPECT/CT is a time-consuming procedure and comprises additional radiation exposure to the patient.
View Article and Find Full Text PDFDetermination of Critical Organ Doses with Lu Prostate-specific Membrane Antigen Dosimetry in Metastatic Prostate Cancer Treatment.
J Med Phys
June 2024
Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Aim: This study aimed to perform dosimetry in patients with metastatic prostate cancer treated with Lutetium (Lu) prostate-specific membrane antigen (PSMA)-617 radiopharmaceutical, calculating organ blood clearance and consequently determining the maximum tolerable treatment activity.
Materials And Methods: Eighteen patients with metastatic prostate cancer were enrolled in the study. Patients were administered 5.